Camilla Soenderby

Camilla Soenderby brings 25 years of international leadership experience from executive roles at top ten biopharma companies in EU, US and Asia. Most recently, Ms. Soenderby was a corporate officer at Takeda, leading global portfolio commercialisation and commercial excellence, overseeing global brands with annual revenue of USD 13 Billion and a large pipeline, working in close partnership with R&D. Prior to that, she worked as SVP, Head of Global Product Strategy for Shire, having previously held regional- and general management positions at Roche Pharma, Abbott (now AbbVie) and Schering Plough. She began her career as a management consultant at McKinsey & Company focused on healthcare.

Camilla currently serves on the Board of Directors of BB Biotech, Abivax and Affibody. She is member of the Novo Advisory Group that supports Novo Holdings in analysing and monitoring its larger life science investments, and an Industrial Advisor for the private equity group EQT.